论文部分内容阅读
目的探讨西地那非联合低分子肝素钙治疗慢性阻塞性肺疾病合并肺源性心脏病患者的疗效。方法选取2015年9月至2016年4月于辽宁省兴城市中医医院就诊的74慢性阻塞性肺疾病合并肺源性心脏病患者作为研究对象,按随机抽签原则将其分为观察组和对照组,各37例。观察组患者采用西地那非联合低分子肝素钙治疗,对照组患者单独应用西地那非治疗,比较两组患者临床疗效、治疗前后肺功能以及血气分析指标变化。结果治疗后,观察组患者的PaO_2明显高于对照组,而PaCO_2则显著低于对照组,差异均有统计学意义(均P<0.05);治疗后,观察组患者的FEV_1、FEV_1/FVC均明显高于对照组,差异均有统计学意义(均P<0.05);观察组患者治疗的总有效率是97.3%,明显高于对照组的78.4%,差异有统计学意义(P<0.05)。结论西地那非联合低分子肝素钙治疗慢性阻塞性肺疾病合并肺源性心脏病临床疗效显著,可有效纠正患者肺功能状态、血气分析指标,从而改善其心肺功能、肺循环状态。
Objective To investigate the efficacy of sildenafil combined with low molecular weight heparin in the treatment of patients with chronic obstructive pulmonary disease and pulmonary heart disease. Methods Seventy-four patients with chronic obstructive pulmonary disease and pulmonary heart disease who were treated in Xingcheng Chinese Medicine Hospital of Liaoning Province from September 2015 to April 2016 were selected as study subjects and divided into observation group and control group , 37 cases in each. Patients in the observation group were treated with sildenafil combined with low molecular weight heparin calcium, while those in the control group were treated with sildenafil alone. The clinical efficacy, changes in lung function and blood gas analysis before and after treatment were compared between the two groups. Results After treatment, the PaO_2 in the observation group was significantly higher than that in the control group, while PaCO_2 was significantly lower than that in the control group (all P <0.05). After treatment, FEV_1 and FEV_1 / FVC in the observation group (P0.05). The total effective rate of treatment group was 97.3%, which was significantly higher than that of control group (78.4%), the difference was statistically significant (P0.05) . Conclusion Sildenafil combined with low molecular weight heparin calcium in patients with chronic obstructive pulmonary disease and pulmonary heart disease clinical significant effect, which can effectively correct the patient’s lung function status, blood gas analysis indicators, thereby improving their cardiopulmonary function, pulmonary circulation status.